Schubert & Co’s Cytokinetics CYTK Stock Holding History

Schubert & Co’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5	Closed	-$176	–	416
2023 Q1	$176	Buy	+5	New	+$204	﹤0.01%	1561

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Schubert & Co's CYTK Position: Q2 2023 in Review

Schubert & Co sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 5 shares — an estimated $176 sold.

Schubert & Co first reported a position in CYTK in Q1 2023 and held it in 1 quarter. The position peaked at $176 in Q1 2023. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

Schubert & Co reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 5 Cytokinetics shares in Q2 2023, an estimated $176.
Schubert & Co first reported a position in Cytokinetics in Q1 2023 and held it in 1 quarter.
Schubert & Co's Cytokinetics position peaked at $176 in Q1 2023.
253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.